Tandem Diabetes Care (TNDM) Non-Current Assets (2013 - 2026)
Tandem Diabetes Care's (TNDM) quarterly Non-Current Assets came in at $266.3 million in Q1 2026, up 2.93% YoY from $258.7 million in Q1 2025, and up 1.26% on a QoQ basis from $263.0 million in Q4 2025.
Tandem Diabetes Care (TNDM) Non-Current Assets (2013 - 2026) Analysis & Trends
Tandem Diabetes Care (TNDM) has 14 years of Non-Current Assets data on file, last reported at $266.3 million in Q1 2026.
- Quarterly Non-Current Assets rose 2.93% year-over-year to $266.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 billion (up 15.04% YoY) and the FY2025 annual result came in at $263.0 million, up 8.14% from the prior year.
- Non-Current Assets climbed to $266.3 million in Q1 2026, from $263.0 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $266.3 million in Q1 2026 to a low of $181.8 million in Q3 2023.
- A 5-year average of $220.2 million and a median of $204.9 million in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets jumped 123.66% — and 2023, when it fell 14.75%.
- Tracing TNDM's Non-Current Assets over 5 years: stood at $202.8 million in 2022, then grew by 0.92% to $204.7 million in 2023, then increased by 18.81% to $243.2 million in 2024, then climbed by 8.14% to $263.0 million in 2025, then climbed by 1.26% to $266.3 million in 2026.
- The last three Non-Current Assets figures came in at $266.3 million (Q1 2026), $263.0 million (Q4 2025), and $257.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.24 Bn | 193.64 Bn | 7.27 Bn | 84.70 Bn |
| 2 | Stryker | 128.63 Bn | 125.15 Bn | 4.50 Bn | 33.51 Bn |
| 3 | Medtronic | 119.19 Bn | 109.97 Bn | 6.41 Bn | 68.24 Bn |
| 4 | Boston Scientific | 73.51 Bn | 72.97 Bn | 3.85 Bn | 37.24 Bn |
| 5 | Edwards Lifesciences | 52.11 Bn | 47.85 Bn | 1.35 Bn | 7.05 Bn |
| 6 | Dexcom | 34.64 Bn | 32.70 Bn | 830.00 Mn | 2.37 Bn |
| 7 | GE HealthCare Technologies | 34.01 Bn | 31.90 Bn | 2.18 Bn | 26.75 Bn |
| 8 | Koninklijke Philips | 26.40 Bn | 23.08 Bn | 4.55 Bn | 20.19 Bn |
| 9 | Steris | 23.14 Bn | 22.65 Bn | 684.20 Mn | 8.29 Bn |
| 10 | Tandem Diabetes Care | 1.57 Bn | 1.11 Bn | 144.78 Mn | 349.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 349.56 Mn |
| Mar 31, 2026 | 266.29 Mn |
| Dec 31, 2025 | 262.97 Mn |
| Sep 30, 2025 | 257.71 Mn |
| Jun 30, 2025 | 260.92 Mn |
| Mar 31, 2025 | 258.71 Mn |
| Dec 31, 2024 | 243.17 Mn |
| Sep 30, 2024 | 204.90 Mn |
| Jun 30, 2024 | 204.12 Mn |
| Mar 31, 2024 | 205.85 Mn |
| Dec 31, 2023 | 204.67 Mn |
| Sep 30, 2023 | 181.77 Mn |
| Jun 30, 2023 | 182.37 Mn |
| Mar 31, 2023 | 196.23 Mn |
| Dec 31, 2022 | 202.81 Mn |
| Sep 30, 2022 | 213.22 Mn |
| Jun 30, 2022 | 201.53 Mn |
| Mar 31, 2022 | 196.81 Mn |
| Dec 31, 2021 | 93.62 Mn |
| Sep 30, 2021 | 95.33 Mn |